Merck Expands Respiratory and Infectious Disease Portfolio with ENFLONSIA Approval

Merck received Health Canada approval for ENFLONSIA, its RSV preventive therapy for infants, expanding its presence in the respiratory and infectious disease space. The approval adds to Merck's growing portfolio in the area, which also includes recent launches and acquisitions. The stock trades at $119.75, with returns of 10.5% over the past week and 41.1% over the past year. The development highlights Merck's efforts to diversify its revenue streams beyond its flagship oncology assets.